Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
15.88
+0.30 (1.93%)
Jun 3, 2026, 2:37 PM EDT - Market open
Theravance Biopharma Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Theravance Biopharma stock has a consensus rating of "Buy" and an average price target of $17.4. The average 1-year stock price forecast is 9.57% higher than the current stock price, while the lowest is $15 (-5.54%) and the highest is $21 (+32.24%).
Price Target: $17.4 (+9.57%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Theravance Biopharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 4 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Buy Maintains $21 | Buy | Maintains | $21 | +32.24% | May 8, 2026 |
| TD Cowen | TD Cowen | Hold Reiterates $15 | Hold | Reiterates | $15 | -5.54% | May 8, 2026 |
| B. Riley Securities | B. Riley Securities | Hold Maintains $14 → $17 | Hold | Maintains | $14 → $17 | +7.05% | Apr 7, 2026 |
| JonesTrading | JonesTrading | Buy Reiterates $17 → $18 | Buy | Reiterates | $17 → $18 | +13.35% | Mar 25, 2026 |
| Oppenheimer | Oppenheimer | Hold Downgrades $27 → $14 | Hold | Downgrades | $27 → $14 | -13.92% | Mar 5, 2026 |
Financial Forecast
Revenue This Year
105.84M
from 107.46M
Decreased by -1.51%
Revenue Next Year
99.94M
from 105.84M
Decreased by -5.57%
EPS This Year
1.82
from 2.06
Decreased by -11.86%
EPS Next Year
0.33
from 1.82
Decreased by -81.80%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 191.6M | 153.3M | ||||||
| Avg | 105.8M | 99.9M | ||||||
| Low | 75.9M | 77.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 78.3% | 44.8% | ||||||
| Avg | -1.5% | -5.6% | ||||||
| Low | -29.4% | -27.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | 2.15 | 0.52 | ||||
| Avg | 1.82 | 0.33 | ||||
| Low | 1.48 | 0.15 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | 4.5% | -71.2% | ||||
| Avg | -11.9% | -81.8% | ||||
| Low | -28.2% | -91.9% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.